Phage Safety Retrospective Cohort Study
Launched by HOSPICES CIVILS DE LYON · Jan 22, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Phage Safety Retrospective Cohort Study, is looking into the safety of a treatment called phage therapy for patients who have had infections in their bones, joints, or implants. The study aims to find out if any side effects experienced by patients after receiving phage therapy are linked to the therapy itself, or if they are related to other treatments like surgery or antibiotics.
To be eligible for this study, patients should have had a bone or joint infection or an implant infection that was treated with phage therapy and experienced some side effects afterward. The trial is currently recruiting participants of all ages and genders. If you take part, you can expect to share your experiences regarding the treatment and any adverse events you may have faced. The goal is to better understand the safety of phage therapy, which could help improve treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients having had a bone or joint or implant infection treated by phagotherapy and having had an adverse event
- Exclusion Criteria:
- • -
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials